检索结果-南通市图书馆

Penpulimab,an anti-PD-1 antibody,for heavily pretreated metastatic nasopharyngeal carcinoma:a single-arm phase II study

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2024年第7期9卷 3056-3062页

作者： Xiaozhong Chen wei wang Qingfeng Zou Xiaodong Zhu Qin Lin Yi Jiang Yan Sun Liangfang Shen Lin wang Guorong Zou Xiaoyan Lin Shaojun Lin Minying Li Ying wang Ruilian Xu Rui Ao Rensheng wang Haifeng Lin Shuang Huang Tingting Xu Wenting Li Mengying Xia Yu Xia Zhongmin wang Baiyong Li Jingao Li Chaosu Hu Department of Radiation Oncology Cancer Hospital of the University of ChineseAcademy of Sciences(Zhejiang Cancer Hospital)HangzhouChina Gastroenterology and Urology Department II Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangshaChina Clinical Research Center for Gastrointestinal Cancer in Hunan Province ChangshaChina Department of Medical Oncology Affiliated Cancer Hospital&Institute of Guangzhou Medical UniversityGuangzhouChina Department of Radiation Oncology Guangxi Medical University Affiliated Tumor Hospital&Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor(Guangxi Medical University)Ministry of Education&Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency TumorGuangxi Medical UniversityNanningChina Department of Radiation Oncology Cancer CenterThe First Affiliated Hospital of Xiamen UniversityXiamenChina Department of Medical Oncology Cancer Hospital of Shantou University Medical CollegeShantouChina Department of Radiation Oncology Peking University Cancer Hospital&InstituteBeijingChina Department of Oncology Xiangya Hospital Central South UniversityChangshaChina Department of Medical Oncology Hainan General HospitalHainan Affiliated Hospital of Hainan Medical UniversityHaikouChina Department of Oncology The Affiliated Panyu Central Hospital of Guangzhou Medical UniversityGuangzhouChina Department of Medical Oncology Fujian Medical University Union HospitalFuzhouChina Department of Radiation Oncology Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhouChina Department of Radiation Therapy for Thoracic Tumors Zhongshan City People’s HospitalZhongshanChina Tumor Radiotherapy Center Chongqing University Cancer HospitalChongqing Cancer HospitalChongqing Cancer InstituteChongqingChina Department of Oncology Shenzhen People’s Hospital(The Second Clinical Medical CollegeJinan UniversityThe First Affiliated HospitalSo

Penpulimab is an anti-programmed cell death-1(PD-1)IgG1 antibody with no Fc gamma receptor(FcγR)binding activity,and thus theoretically reduced immune-related adverse events(irAEs)while maintaining *** single-arm,phase II trial conducted across 2. tertiary care centers in China enrolled adult patients with metastatic nasopharyngeal carcinoma(NPC)who had failed two or more lines of previous systemic *** received 2.0-mg penpulimab intravenously every 2.weeks(4 weeks per cycle)until disease progression or intolerable *** primary endpoint was objective response rate(ORR)per RECIST(version 1.1),as assessed by an independent radiological review *** secondary endpoints included progression-free survival(PFS)and overall survival(OS).One hundred thirty patients were enrolled and 12. were efficacy *** the data cutoff date(September 2.,2.2.),1 patient achieved complete response and 34 patients attained partial *** ORR was 2..0%(95%CI 2..3–36.7%).The response was durable,with 66.8%still in response at 9 ***-three patients(2..4%)were still on *** median PFS and OS were 3.6 months(95%CI=1.9–7.3 months)and 2..8 months(95%CI=17.1 months to not reached),***(7.6%)patients experienced grade 3 or higher *** has promising anti-tumor activities and acceptable toxicities in heavily pretreated metastatic NPC patients,supporting further clinical development as third-line treatment of metastatic NPC.

关键词： metastatic nasopharyngeal supporting

Echocardiographic Measurements in Normal Chinese Adults(EMINCA)II focusing on left ventricular and left atrial size and function by three-dimensional echocardiography

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Frontiers of Medicine 2024年第4期18卷 649-663页

作者： Yingbin wang Yu Zhang Guihua Yao Hong Tang Lixin Chen Lixue Yin Tiangang Zhu Jianjun Yuan wei Han Jun Yang Xianhong Shu Ya Yang Yulin wei Yanli Guo weidong Ren Dongmei Gao Guilin Lu Ji Wu Hongning Yin Yuming Mu Jiawei Tian Lijun Yuan Xiaojing Ma Hongyan Dai Yunchuan Ding Mingyan Ding Qing Zhou Hao wang Di Xu Mei Zhang Yun Zhang State Key Laboratory for Innovation and Transformation of Luobing Theory Key Laboratory of Cardiovascular Remodeling and Function ResearchChinese Ministry of EducationChinese National Health Commission and Chinese Academy of Medical SciencesDepartment of CardiologyQilu Hospital of Shandong UniversityJinan250012China Department of Cardiology Qilu Hospital of Shandong University(Qingdao)Qingdao266000China Department of Ultrasonography West China HospitalSichuan UniversityChengdu610041China Department of Ultrasonography Shenzhen People’s Hospital/The Second Clinical Medical College of Jinan UniversityShenzhen518020China Department of Ultrasonography Electronic Science and Technology University of ChinaThe Affiliated Sichuan Provincial People’s HospitalChengdu610072China Department of Cardiology Peking University People’s HospitalBeijing100044China Department of Ultrasonography Henan Provincial People’s HospitalZhengzhou463599China Department of Cardiology The First Affiliated Hospital of Harbin Medical UniversityHarbin150007China Department of Echocardiology The First Affiliated Hospital of China Medical UniversityShenyang110001China Department of Echocardiology Zhongshan HospitalFudan UniversityShanghai200032China Department of Echocardiology Beijing Anzhen HospitalCapital Medical UniversityBeijing100029China Department of Cardiology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou510120China Department of Ultrasonography The Southwest Hospital of AMUChongqing400038China Department of Ultrasonography Shengjing Hospital of China Medical UniversityShenyang110136China Department of Ultrasonography China-Japan Union hospital of Jilin UniversityChangchun130033China Department of Ultrasonography First Affiliated HospitalSchool of MedicineShihezi UniversityShihezi832000China Department of Ultrasonography The First Affiliated Hospital of Guangxi Medical UniversityNanning537406China Department of Echocardiology The Second Hospital of Hebei Medical Uni

Current guidelines encourage large studies in a diverse population to establish normal reference ranges for three-dimensional(3D)echocardiography for different ethnic *** study was designed to establish the normal values of 3D-left ventricular(LV)and left atrial(LA)volume and function in a nationwide,population-based cohort of healthy Han Chinese adults.A total of 1117 healthy volunteers aged 18–89 years were enrolled from 2. collaborating laboratories in *** sets of 3D echocardiographic instruments were used,and full-volume echocardiographic images were recorded and transmitted to a core laboratory for image analysis with a vendor-independent off-line ***,866 volunteers(mean age of 48.4 years,402.men)were qualified for final *** parameters exhibited substantial differences between different sex and age groups,even after indexation by body surface *** normal ranges of 3D-LV and 3D-LA volume and function differed from those recommended by the American Society of Echocardiography and the European Association of Cardiovascular Imaging guidelines,presented by the World Alliance Societies of Echocardiography(WASE)study,and from the 2. values in the EMINCA *** normal reference values of 3D echocardiography-derived LV and LA volume and function were established for the first time in healthy Han Chinese *** ranges of 3D-LV and 3D-LA echocardiographic measurements stratified with sex,age,and race should be recommended for clinical applications.

关键词： three-dimensional echocardiography left ventricle left atrium normal reference values Chinese adults

Machine learning identifies the risk of complications after laparoscopic radical gastrectomy for gastric cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2024年第1期30卷 79-90页

作者： Qing-Qi Hong Su Yan Yong-Liang Zhao Lin Fan Li Yang Wen-Bin Zhang Hao Liu He-Xin Lin Jian Zhang Zhi-Jian Ye Xian Shen Li-Sheng Cai Guo-wei Zhang Jia-Ming Zhu Gang Ji Jin-Ping Chen wei {2. Zheng-Rong Li Jing-Tao Zhu Guo-Xin Li Jun You Department of Gastrointestinal Oncology Surgery The First Affiliated Hospital of Xiamen UniversitySchool of MedicineXiamen 361001Fujian ProvinceChina Department of Gastrointestinal Surgery Qinghai University Affiliated HospitalXining 810000Qinghai ProvinceChina Department of General Surgery and Center of Minimal Invasive Gastrointestinal Surgery The First Hospital Affiliated to Army Medical UniversityChongqing 400038China Department of General Surgery The First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an 710061Shaanxi ProvinceChina Department of General Surgery The First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029Jiangsu ProvinceChina Department of Gastrointestinal Surgery The First Affiliated Hospital of Xinjiang Medical UniversityUrmuqi 830054Xinjiang Uygur Autonomous RegionChina Department of General Surgery Nanfang HospitalSouthern Medical UniversityGuangzhou 510515Guangdong ProvinceChina Department of Gastrointestinal Surgery Affiliated Hangzhou First People's HospitalZhejiang University School of MedicineHangzhou 310006Zhejiang ProvinceChina Department of Gastrointestinal Surgery Zhongshan Hospital of Xiamen UniversityXiamen 361004Fujian ProvinceChina Department of Surgery The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical UniversityWenzhou 325027Zhejiang ProvinceChina Department of General Surgery Unit 4 Zhangzhou Affiliated Hospital of Fujian Medical UniversityZhangzhou 363000Fujian ProvinceChina Department of Gastrointestinal Surgery The Second Affiliated Hospital of Xiamen Medical CollegeXiamen 361021Fujian ProvinceChina Department of Gastrointestinal Nutrition and Hernia Surgery The Second Hospital of Jilin UniversityChangchun 130041Jilin ProvinceChina Department of Digestive Diseases Xijing HospitalAir Force Military Medical UniversityXi'an 710032Shaanxi ProvinceChina Department of Gastrointestinal Surgery Quanzhou First Hospital Affiliated to Fujian Medical UniversityQuanzhou 362002Fujian Provin

BACKGROUND Laparoscopic radical gastrectomy is widely used,and perioperative complications have become a highly concerned *** To develop a predictive model for complications in laparoscopic radical gastrectomy for gastric cancer to better predict the likelihood of complications in gastric cancer patients within 30 days after surgery,guide perioperative treatment strategies for gastric cancer patients,and prevent serious *** In total,998 patients who underwent laparoscopic radical gastrectomy for gastric cancer at 16 Chinese medical centers were included in the training group for the complication model,and 398 patients were included in the validation *** clinicopathological data and 30-d postoperative complications of gastric cancer patients were *** machine learning methods,lasso regression,random forest,and artificial neural networks,were used to construct postoperative complication prediction models for laparoscopic distal gastrectomy and laparoscopic total gastrectomy,and their prediction efficacy and accuracy were *** The constructed complication model,particularly the random forest model,could better predict serious complications in gastric cancer patients undergoing laparoscopic radical *** exhibited stable performance in external validation and is worthy of further promotion in more *** Using the risk factors identified in multicenter datasets,highly sensitive risk prediction models for complications following laparoscopic radical gastrectomy were *** hope to facilitate the diagnosis and treatment of preoperative and postoperative decision-making by using these models.

关键词： Gastric cancer Laparoscopic radical gastrectomy Postoperative complications Laparoscopic total gastrectomy

Shanghai Gynecologic Oncology Group’s consensus on the academic and industry’s clinical trial types

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第14期137卷 1744-1746页

作者： Shi Tingyan Liu Jihong Zhu Jianqing wang Xipeng Jiang wei Lu Xin Feng weiwei Zhou Shengtao Shen Yang Chen Gang Wu Zhenyu Zou Dongling Wu Peng Yang Huijuan Wu Sufang Zhu Tao wang Huaying Zhang Yingli Qiu Lihua Guo Xiaoqing Xiang Libing Zhang wei Ren Yulan Feng Yanling Liu Yanfei Chen Xiaojun Zang Rongyu Department of Gynecologic Oncology Fudan University Zhongshan Hospital Institute for Ovarian Cancer Fudan University Shanghai China Department of Gynecologic Oncology Sun Yat-Sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong China Department of Gynecologic Oncology Zhejiang Cancer Hospital Hangzhou Zhejiang China Department of Obstetrics and Gynecology Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China Department of Gynecology Obstetrics and Gynecology Hospital Fudan University Shanghai China Department of Obstetrics and Gynecology Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China Department of Obstetrics and Gynecology Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy West China Second Hospital Sichuan University and Collaborative Innovation Center Chengdu Sichuan China Department of Obstetrics and Gynecology Zhongda Hospital School of Medicine Southeast University Nanjing Jiangsu China National Clinical Research Center for Gynecology and Obstetrics Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China school of Public Health Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health Fudan University Shanghai China Gynecologic Oncology Center Chongqing University Cancer Hospital Chongqing China Department of Obstetrics and Gynecology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China Department of Gynecologic Oncology Fudan University Shanghai Cancer Center Shanghai China Department of Obstetrics and Gynecology Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai China Department of Obstetrics and Gynecology Renji Hospital School of Medicine

Shanghai Gynecologic Oncology Group (SGOG, www. ***), established in 2.09, is a non-profit organization of clinical research and the full member of Gynecology Cancer Intergroup (GCIG) since 2.12. It was guided by Drs. Jinghe Lang (China), Gavin Stuart (Canada) (2.09-2.2.); Drs. Jinghe Lang (China), Ding Ma (China) (2.2.-) and was supported by Dr. Zeyi Cao (2.09-2.12.. The mission of SGOG is to actively promote the investigator-initiated trial (IIT) in gynecologic cancers, particularly the innovative phase II clinical trials. Followed by the high quality of management in investigators’ training, trial development, human resources, and research funding, SGOG has initiated phase III clinical trials to improve the future clinical practice. SGOG aims to obtain reliable data by conducting systematic, standardized, and high-quality clinical trials, to guide the clinical practice of ovarian cancer, endometrial cancer, and cervical cancer in China. SGOG holds group meetings twice a year, and actively participates in GCIG international communication and cooperation that expands its international and national influence in the field of clinical research in gynecologic cancers. This coordination is not only particularly relevant between academic groups but also with national and/or international industry partners.

关键词：

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2.2.

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2024年第1期44卷 127-172页

作者： Feng-Hua wang Xiao-Tian Zhang Lei Tang Qi Wu Mu-Yan Cai Yuan-Fang Li Xiu-Juan Qu Hong Qiu Yu-Jing Zhang Jie-Er Ying Jun Zhang Ling-Yu Sun Rong-Bo Lin Chang wang Hao Liu Miao-Zhen Qiu Wen-Long Guan Sheng-Xiang Rao Jia-Fu Ji Yan Xin {2.-Qi Sheng Hui-Mian Xu Zhi-{2. Zhou Ai-Ping Zhou Jing Jin Xiang-Lin Yuan Feng Bi Tian-Shu Liu Han Liang Yan-Qiao Zhang Guo-Xin Li Jun Liang Bao-Rui Liu Lin Shen Jin Li Rui-Hua Xu Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer HospitalBeijingP.R.China Department of Radiology Peking University Cancer HospitalBeijingP.R.China Department of Endoscopy Center Peking University Cancer HospitalBeijingP.R.China Department of Pathology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineGuangzhouGuangdongP.R.China Department of Gastric Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Medical Oncology The First Hospital of China Medical UniversityShenyangLiaoningP.R.China Department of Medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubeiP.R.China Department of Radiotherapy Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Medical Oncology Zhejiang Cancer HospitalHangzhouZhejiangP.R.China Department of Medical Oncology Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R.China Department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiangP.R.China Department of Medical Oncology Fujian Cancer HospitalFuzhouFujianP.R.China Tumor Center The First Hospital of Jilin UniversityChangchunJilinP.R.China Department of General Surgery Nanfang HospitalSouthern Medical UniversityGuangzhouGuangdongP.R.China Department of Radiology Zhongshan HospitalFudan UniversityShanghaiP.R.China Department of

The 2.2. update of the Chinese Society of Clinical Oncology(CSCO)Clini-cal Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China,reflecting the latest advancements in evidence-based medicine,healthcare resource availability,and precision *** updates address the differences in epidemiological characteristics,clinicopatho-logical features,tumor biology,treatment patterns,and drug selections between Eastern and Western gastric cancer *** revisions include a structured template for imaging diagnosis reports,updated standards for molecular marker testing in pathological diagnosis,and an elevated recommendation for neoadju-vant chemotherapy in stage III gastric *** advanced metastatic gastric cancer,the guidelines introduce new recommendations for immunotherapy,anti-angiogenic therapy and targeted drugs,along with updated management strategies for human epidermal growth factor receptor 2.HER2.-positive and deficient DNA mismatch repair(dMMR)/microsatellite instability-high(MSI-H)***,the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric *** 2.2. CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice,particularly in the heterogeneous healthcare landscape of China,while maintaining a commitment to scientific rigor,impartiality,and timely revisions.

关键词： Chinese Society of Clinical Oncology(CSCO) gastric cancer diagnosis surgery neoadjuvant adjuvant radiotherapy chemotherapy targeted therapy immunotherapy

One-year status of hepatic venous pressure gradient measurement from 85 hospitals in China

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Portal Hypertension & Cirrhosis 2024年第2期3卷 116-123页

作者： Jitao wang Ting Cui Linpeng Zhang Zhiping Yan Lei Li Jinjun Chen Junhui Sun Hua Xiang He Zhu Hao Wu Jiancuo Gengzang Feng Zhang wei Wu Guohong Cao Wuhua Guo Haibin Shi Hui Xue Guangjun Huang Qiang Yu Meng Niu Huiling Xiang Derun Kong wei Gou Xuefeng Luo Fuliang He Min Yuan wei Liu Yong wang Hongjie Hu Xiaoli Zhu Tao Yu Qinxue Sun wei Qu Ting Lu Deqiang Ma Li Zhang Jun Ma Jun Yang Ketao Mu Xiaoliang Zhu Kai Xiong Huiguo Ding Shengjuan Yao Mingsheng Huang Fang wang Zexin wang Yong Huang Jianan Li Hongfeng Yi Birun Huang Zhongwei Zhao Duiping Feng yanming Lei Changlong Hou Wenbo Guo Shirong Liu Gaojun Teng Kangshun Zhu Fan Wu Xiaogang Hu Wenfeng Zhang Shaoqi Yang Zhouchao Hu Pengfei Pang Shaowu Zhuang weidong wang Qingliang Zhu Kunpeng Zhang Chengyu Liu Dongliang Li Chao Ma Hong Jiang Xingong Zhao weixin Ren Zhiwei wang Lei Yu Fuhuang Lin Chaoguang Yan Feng wang Lei Yu Hui Huan Wenyong Shen Shaofei He Chengda Zhang Jinlun Bao Jiangtao Liu Jun Wu Jianbo Zhao Jian Zhang Xiaolong Qi Hebei Provincial Key Laboratory of Cirrhosis&Portal Hypertension Xingtai People's HospitalXingtaiHebeiChina Center of Portal Hypertension Department of RadiologyZhongda HospitalSchool of MedicineSoutheast UniversityNanjingJiangsuChina Department of Interventional Therapy Beijing Shijitan Hospital Affiliated to Capital Medical UniversityBeijingChina Department of Intervention Taiyuan Third People's HospitalTaiyuanShanxiChina Department of Intervention Zhongshan Hospital Affiliated to Fudan UniversityShanghaiChina Department of Interventional Medicine The First Hospital of Lanzhou UniversityLanzhouGansuChina Department of Infectious Diseases Nanfang Hospital of Southern Medical UniversityGuangzhouGuangdongChina Hepatobiliary and Pancreatic Intervention Center The First Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiangChina Interventional Vascular Surgery Hunan Provincial People's HospitalChangshaHunanChina Department of Intervention Sixth People's Hospital of ShenyangShenyangLiaoningChina Department of Gastroenterology West China Hospital of Sichuan UniversityChengduSichuanChina Department of Intervention The Fourth People's Hospital of Qinghai ProvinceXiningQinghaiChina Department of Gastroenterology Nanjing Drum Tower HospitalNanjingJiangsuChina Department of Gastroenterology The First Affiliated Hospital of Wenzhou Medical UniversityWenzhouZhejiangChina Department of Radiology Shulan(Hangzhou)HospitalHangzhouZhejiangChina Department of Intervention Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhouFujianChina Department of Interventional Radiology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChina Department of Gastroenterology The First Affiliated Hospital of Xi'an Jiaotong UniversityXi'anShaanxiChina Department of Gastroenterology Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinanShandongChina Department of Interventional Radiology Fifth Medical Center

Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in *** article aimed to investigate the status of hepatic venous pressure gradient measurement in China in ***:We investigated the overall status of HVPG technology in China-including hospital distribution,hospital level,annual number of cases,catheters used,average cost,indications,and current challenges by using online *** counting the number and percentages of cases of these results,we hope to clarify the current status of HVPG measurements in ***:According to the survey,85 hospitals in China used HVPG technology in 2.2. distributed across 2. provinces.A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2.2.,of which 2.13 cases(56.4%)were measured *** average cost of HVPG measurement was 5646.8±2.2..9 *** the clinical teams who performed the measurements(sometimes multiple per hospital),94.3%(82.87)used the balloon method,and the majority of the teams(72.4%,63/87)used embolectomy ***:This survey clarified the clinical application status of HVPG in China and confirmed that some medical institutions in China have established a foundation for this *** is still necessary to continue promoting and popularizing this technology in the future.

关键词： application status hepatic vein pressure gradient questionnaire survey

Using choroidal thickness to detect myopic macular degeneration

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Ophthalmology(English edition) 2024年第2期17卷 317-323页

作者： Ran Liu Meng Xuan De-Cai wang Ou Xiao Xin-Xing Guo Jian Zhang wei wang Monica Jong Padmaja Sankaridurg Kyoko Ohno-Matsui Qiu-Xia Yin Ming-Guang He Zhi-Xi Li State Key Laboratory of Ophthalmology Zhongshan Ophthalmic CenterSun Yat-sen UniversityGuangdong Provincial Key Laboratory of Ophthalmology and Visual ScienceGuangdong Provincial Clinical Research Center for Ocular DiseasesGuangzhou 510060Guangdong ProvinceChina New England college of Optometry BostonMassachusetts 02115USA Wilmer Eye Institute Johns Hopkins UniversityBaltimoreMD 21231USA Brien Holden Vision Institute Sydney 2052Australia school of Optometry and Vision Science University of New South WalesSydney 2052Australia Department of Ophthalmology and Visual Science Tokyo Medical and Dental UniversityTokyo 113-8510Japan school of Optometry the Hong Kong Polytechnic UniversityHong Kong SARChina Research Centre for SHARP Vision the Hong Kong Polytechnic UniversityHong Kong SARChina Center for Eye and Vision Research(CEVR) 17W Hong Kong Science ParkHong Kong SARChina

AIM:To explore the usage of choroidal thickness measured by swept-source optical coherence tomography(SS-OCT)to detect myopic macular degeneration(MMD)in high myopic ***:Participants with bilateral high myopia(≤−6 diopters)were recruited from a subset of the guangzhou zhongshan Ophthalmic Center-Brien Holden Vision Institute High Myopia Cohort ***-OCT was performed to determine the choroidal thickness,and myopic maculopathy was graded by the International Meta-Analysis for Pathologic Myopia(META-PM)Classiﬁ*** of MMD was defined as META-PM category 2.or ***:A total of 568 right eyes were included for *** with MMD(n=106,18.7%)were found to have older age,longer axial lengths(AL),higher myopic spherical equivalents(SE),and reduced choroidal thickness in each Early Treatment Diabetic Retinopathy Study(ETDRS)grid sector(P2.9,0.82.8,and 0.82.5,*** choroidal thickness of the inner and outer nasal sectors was the most accurate indicator of MMD(AUC of 0.92. and 0.92.,respectively).An outer nasal sector choroidal thickness of less than 74μm demonstrated the highest odds of predicting MMD(OR=33.8).CONCLUSION:Choroidal thickness detects the presence of MMD with high agreement,particularly of the inner and outer nasal sectors of the posterior pole,which appears to be a biometric parameter more precise than age,AL,or SE.

关键词： high myopia choroidal thickness myopic macular degeneration swept-source optical coherence tomography

珠三角地区老年人养老需求、服务偏好及养老倾向的城乡差异性分析

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国医学科学院学报 2024年第2期46卷 193-203页

作者：杨华杰黄翔梁家斌贾至慧卫庆国王皓翔广东开放大学(广东理工职业学院)健康产业学院广东中山528400 广东省中山市三乡镇社区卫生服务中心公共卫生业务管理科广东中山528463 澳门科技大学医学院中国澳门特别行政区999078 中山大学公共卫生学院广州510080 广东省基层卫生协会青年骨干分会广州510000

目的了解珠三角地区常住老年人养老需求、服务偏好及养老倾向的城乡差异,为科学规划和配置城乡养老资源提供参考。方法采用多阶段分层随机抽样方法,在珠三角地区选取2.地级市的7个社区卫生服务中心,对到中心就诊的1919名60岁及以上的... 详细信息

目的了解珠三角地区常住老年人养老需求、服务偏好及养老倾向的城乡差异,为科学规划和配置城乡养老资源提供参考。方法采用多阶段分层随机抽样方法,在珠三角地区选取2.地级市的7个社区卫生服务中心,对到中心就诊的1919名60岁及以上的城乡常住老年人进行有关养老需求、服务偏好及养老倾向的问卷调查。结果共调查珠三角地区城市老年人641人(33.4%),农村老年人12.8人(66.6%);城市老年人和农村老年人的子女情况(χ^(2.=43.379,P2.=104.141,P2.=65.632.P2.=41.373,P2.2.)显著高于农村老年人(44.0%)(χ^(2.=57.007,P<0.001)。以家庭养老为参照,城市老年人中家庭月收入与支出有余和基本持平的选择机构养老和社区居家养老的倾向均更低,城市男性、大专及以上文化程度、有购买社会化养老服务项目需求的老年人更偏好社区居家养老;本地户籍的农村老年人更倾向于选择机构养老和社区居家养老,非独生子女、对生活状况感到满意的农村老年人选择社区居家养老的意愿更低。结论应充分考虑老年人在养老需求、服务偏好及养老倾向存在的城乡差异,科学规划和合理配置城乡养老资源,结合城乡地区特点因地制宜发展多元化的社会养老服务。

关键词：城乡差异养老需求养老服务偏好养老倾向

维普期刊数据库

同方期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

基于大语言模型的糖尿病管理:潜力与展望

Science Bulletin 2024年第5期69卷 583-588页

作者：盛斌管洲榆 Lee-Ling Lim 江泽铧 Nestoras Mathioudakis 李佳佳刘茹涵包玉倩 Yong Mong Bee 王亚星郑颖丰 Gavin Siew wei Tan 纪宏伟 Josip Car 王海波 David C.Klonoff 李华婷覃宇宗黄天荫贾伟平 Shanghai International Joint Laboratory of Intelligent Prevention and Treatment for Metabolic Diseases Department of Computer Science and EngineeringSchool of ElectronicInformationand Electrical EngineeringShanghai Jiao Tong UniversityDepartment of Endocrinology and MetabolismShanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai Diabetes InstituteShanghai Clinical Center for DiabetesShanghai 200240China MOE Key Laboratory of Artificial Intelligence Artificial Intelligence InstituteShanghai Jiao Tong UniversityShanghai 200240China Department of Medicine Faculty of MedicineUniversity of MalayaKuala Lumpur 50603Malaysia Department of Medicine and Therapeutics The Chinese University of Hong KongHong KongChina Asia Diabetes Foundation Hong KongChina Tsinghua Medicine of Tsinghua university Beijing 100084China school of Clinical Medicine Beijing Tsinghua Changgung HospitalBeijing 102218China Division of Endocrinology Diabetes&MetabolismJohns Hopkins University School of MedicineBaltimoreMD 21211USA Department of Endocrinology Singapore General HospitalSingapore 169608Singapore Beijing Institute of Ophthalmology Beijing Tongren HospitalCapital University of Medical ScienceBeijing Ophthalmology and Visual Sciences Key LaboratoryBeijing 100730China State Key Laboratory of Ophthalmology Zhongshan Ophthalmic CenterSun Yat-sen UniversityGuangdong Provincial Key Laboratory of Ophthalmology and Visual ScienceGuangzhou 510060China Singapore Eye Research Institute Singapore National Eye CentreSingapore 168751Singapore Department of Cardiology the Affiliated Hospital of Qingdao UniversityQingdao 266011China Centre for Population Health Sciences Lee Kong Chian School of MedicineNanyang Technological University SingaporeSingapore 639798Singapore Department of Primary Care and Public Health School of Public HealthImperial College LondonLondon SW72BUUK Clinical Trial Unit Research Centre of Big Data and Artificial Intelligence in Medicine

The increasing prevalence of diabetes has become a global public health concern in the 2.st *** 2.2.,it was estimated that 537 million people had diabetes,and this number is projected to reach 643 million by 2.30,and 783 million by 2.45[1].Such a huge burden of diabetes brings great challenges in its prevention and management,including early diagnosis,timely interventions,and regular monitoring of risk factor control and complications *** self-care support and patient empowerment can enhance clinical and psychobehavioural outcomes[2.,although these require additional resources including manpower,infrastructure(hard and technology),and *** emergence of digital health technologies(DHTs),especially artificial intelligence(AI),may help address these obstacles and alleviate the burden of diabetes[3].Large language models(LLMs),a generative AI that can accept image and text inputs and produce text outputs,have shown promise in various aspects of medical care.

关键词： prevention diagnosis finance